A dermatology company, which is engaged in the development and marketing Levulan photodynamic therapy and other products for common skin conditions.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Pharm micro-cap with a good balance sheet and real revenues with a few established products (primary one is Levulan Kerastick).http://seekingalpha.com/article/222372-dusa-a-great-value-in-micro-cap-biotech
MagicDiligence.com stats:
Instant Diligence:
The Earnings Yield of 2.3% is Very Low.
The MFI Return on Capital of 90.2% is Very High.
Near-term Financial Health appears to be Excellent. The current ratio is 4.84.
Calculations:
(for quarter ended 2010-12-31)
Market Cap = Stock_Price * Shares
= 5.76 * 24.77
= 142.65
Excess Cash = Cash - MAX(0; (Current Liabilities - Current Assets + Cash))
= 19.65 - MAX(0; (5.47 - 26.47 + 19.65))
= 19.65
Enterprise Value = Market Cap + Total Debt - Excess Cash
= 142.65 + 0.00 - 19.65
= 123.00
MFI Invested Capital = Total Assets - Goodwill - Intangibles - Current Liabilities + Short Term Debt - Excess Cash
= 28.29 - 0.00 - 0.00 - 5.47 + 0.00 - 19.65
= 3.18
Earnings Yield = Operating Earnings / Enterprise Value
= 2.87 / 123.00
= 0.023 (2.3%)
MFI Return on Capital = Operating Earnings / MFI Invested Capital
= 2.87 / 3.18
= 0.902 (90.2%)